Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Takeda Oncology on X: "Multiple #myeloma may be the most common, but DYK there are several other forms of myeloma? Take action, learn more https://t.co/aDKofURa4c https://t.co/aFizSxMTn0" / X
How I treat high-risk multiple myeloma - ScienceDirect
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology
Carfilzomib in multiple myeloma | PPT
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology
Multiple myeloma | Nature Reviews Disease Primers
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Kyprolis® Treatment for Patients With Multiple Myeloma - CancerConnect
Cardiovascular Complications of Novel Multiple Myeloma Treatments | Circulation
Frontiers | Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Carfilzomib in multiple myeloma | PPT
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology
Emerging immunotherapies in multiple myeloma | The BMJ
Cancers | Free Full-Text | Genome Instability in Multiple Myeloma: Facts and Factors
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Dr. Reddy's Laboratories Ltd. - Multiple myeloma is a cancer of plasma cells that generally affects people in the age group of 52-61 years and early diagnosis is possible with routine blood
The Changing Face of Multiple Myeloma | GoToPER.com
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
